With increasing cases of drug failure, due to problems associated with pharmacokinetic profiles of candidate therapies, absorption, distribution, metabolism and excretion (ADME)
Nearly 60% of these companies are small and mid-sized firms. Further, close to 35% of the CROs engaged in this domain, claim to provide services to both pharmaceutical companies and academic institutes.